849636--4/15/2009--CORTEX_PHARMACEUTICALS

related topics

{stock, price, share}

{product, candidate, development}

{control, financial, internal}

{product, market, service}

{regulation, government, change}

{personnel, key, retain}

{property, intellectual, protect}

{interest, director, officer}

{acquisition, growth, future}

{provision, law, control}

{product, liability, claim}

Risks related to our business Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. We have a history of net losses; we expect to continue to incur net losses and we may never achieve or maintain profitability. If we are unable to progress in our clinical development of A MPAKINE CX717 for an acute indication in a timely manner, or at all, there could be a significant negative impact on our business operations and the market price of our common stock. We will need additional capital in the future and, if it is not available on terms acceptable to us, or at all, we may need to scale back our research and development efforts and may be unable to continue our business operations. Our products rely on licenses from The Regents of the University of California and The Governors of the University of Alberta, and if we lose access to these technologies or applications, our business would be substantially impaired. We are at an early stage of development and we may not be able to successfully develop and commercialize our products and technologies. We may not be able to enter into the strategic alliances necessary to fully develop and commercialize our products and technologies, and we will be dependent on our corporate partners if we do. If we are unable to maintain our relationships with academic consultants and the University of California, Irvine, our business could suffer. Risks related to our industry If we fail to secure adequate intellectual property protection, it could significantly harm our financial results and ability to compete. We may be subject to potential product liability claims. One or more successful claims brought against us could materially impact our business and financial condition. We face intense competition that could result in products that are superior to the products that we are developing. We may be unable to recruit and retain our senior management and other key technical personnel on whom we are dependent. The regulatory approval process is expensive, time consuming, uncertain and may prevent us from obtaining required approvals for the commercialization of some of our products. Our stock price may be volatile and our common stock could decline in value. There is a large number of shares of common stock that may be sold, which may depress the market price of our stock. Our charter document and shareholder rights plan may prevent or delay an attempt by our stockholders to replace or remove management. We may be unable to maintain the standards for listing on the NYSE Amex, which could adversely affect the liquidity of our common stock. If our common stock were delisted and determined to be a penny stock, a broker-dealer may find it more difficult to trade our common stock and an investor may find it more difficult to acquire or dispose of our common stock in the secondary market.

Full 10-K form ▸

849636--4/15/2009--CORTEX_PHARMACEUTICALS_INC/DE/